SCOPUS 정보 검색 플랫폼

Nature Reviews Clinical Oncology

Volumn 9, Issue 4, 2012, Pages 194-196

Gynecological cancer: First-line bevacizumab for ovarian cancer - New standard of care?

(2) Banerjee, Susana a Kaye, Stan B b

a INSTITUTE OF CANCER RESEARCH (United Kingdom)

b ROYAL MARSDEN HOSPITAL (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GEMCITABINE; PACLITAXEL; PLACEBO;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY; STOMACH CANCER; TREATMENT DURATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; STANDARD OF CARE;

EID: 84859443158 PISSN: 17594774 EISSN: 17594782 Source Type: Journal
DOI: 10.1038/nrclinonc.2012.28 Document Type: Short Survey

Times cited : (9)

References (7)

1
- 84855425106
- Incorporation of bevacizumab in the primary treatment of ovarian cancer
- Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473-2483 (2011).
- (2011) N. Engl. J. Med. , vol.365 , pp. 2473-2483
- Burger, R.A.¹

2
- 84855466019
- A phase 3 trial of bevacizumab in ovarian cancer
- Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484-2496 (2011).
- (2011) N. Engl. J. Med. , vol.365 , pp. 2484-2496
- Perren, T.J.¹

3
- 84859438516
- Committee for Medicinal Products for Human Use
- Committee for Medicinal Products for Human Use. Summary of opinion (post authorisation): Avastin [online], http://www.ema.europa.eu/docs/en-GB/document- library/Summary-of-opinion/human/000582/WC500112811.pdf (2011).
- (2011) Summary of Opinion (Post Authorisation): Avastin [Online]

4
- 80053246700
- The role of targeted therapy in ovarian cancer
- Banerjee, S. & Kaye, S. The role of targeted therapy in ovarian cancer. Eur. J. Cancer 47 (Suppl. 3), S116-S130 (2011).
- (2011) Eur. J. Cancer , vol.47 , Issue.SUPPL. 3
- Banerjee, S.¹ Kaye, S.²

5
- 33947311852
- What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
- Han, E. S. & Monk, B. J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol. Oncol. 105, 3-6 (2007).
- (2007) Gynecol. Oncol. , vol.105 , pp. 3-6
- Han, E.S.¹ Monk, B.J.²

6
- 80053229517
- OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
- abstract
- Aghajanian, C. et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [abstract]. J. Clin. Oncol. 29 (Suppl.), LBA5007 (2011).
- (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL.
- Aghajanian, C.¹

7
- 79953252011
- Targeted therapies: Bevacizumab-has it reached its final resting place?
- Kerr, D. J. & Young, A. M. Targeted therapies: bevacizumab-has it reached its final resting place? Nat. Rev. Clin. Oncol. 8, 195-196 (2011).
- (2011) Nat. Rev. Clin. Oncol. , vol.8 , pp. 195-196
- Kerr, D.J.¹ Young, A.M.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.